Sentiment-Signal
9,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Unternehmen & Branche
| Name | Esperion Therapeutics, Inc. |
|---|---|
| Ticker | ESPR |
| CIK | 0001434868 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 401,3 Mio. USD |
| Beta | 1,17 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 403,135,000 | -22,682,000 | -0.11 | 465,886,000 | -301,965,000 |
| 2025-09-30 | 10-Q | 87,309,000 | -31,333,000 | -0.16 | 364,020,000 | -451,361,000 |
| 2025-06-30 | 10-Q | 82,385,000 | -12,725,000 | -0.06 | 347,085,000 | -433,509,000 |
| 2025-03-31 | 10-Q | 64,995,000 | -40,455,000 | -0.21 | 324,029,000 | -426,211,000 |
| 2024-12-31 | 10-K | 332,314,000 | -51,745,000 | -0.28 | 343,821,000 | -388,722,000 |
| 2024-09-30 | 10-Q | 51,632,000 | -29,524,000 | -0.15 | 314,114,000 | -370,209,000 |
| 2024-06-30 | 10-Q | 73,834,000 | -61,925,000 | -0.33 | 352,319,000 | -344,220,000 |
| 2024-03-31 | 10-Q | 137,735,000 | 61,022,000 | 0.34 | 373,060,000 | -294,298,000 |
| 2023-12-31 | 10-K | 116,334,000 | -209,248,000 | -2.03 | 205,796,000 | -454,994,000 |
| 2023-09-30 | 10-Q | 33,969,000 | -41,250,000 | -0.37 | 221,305,000 | -410,004,000 |
| 2023-06-30 | 10-Q | 25,786,000 | -49,935,000 | -0.46 | 234,626,000 | -371,978,000 |
| 2023-03-31 | 10-Q | 24,329,000 | -61,719,000 | -0.79 | 251,819,000 | -329,663,000 |
| 2022-12-31 | 10-K | 75,475,000 | -233,659,000 | -3.52 | 247,939,000 | -323,778,000 |
| 2022-09-30 | 10-Q | 18,980,000 | -55,117,000 | -0.81 | 312,827,000 | -294,100,000 |
| 2022-06-30 | 10-Q | 18,841,000 | -66,324,000 | -1.05 | 303,980,000 | -291,698,000 |
| 2022-03-31 | 10-Q | 18,836,000 | -56,731,000 | -0.93 | 342,853,000 | -249,040,000 |
| 2021-12-31 | 10-K | 78,447,000 | -269,108,000 | -9.31 | 381,590,000 | -196,944,000 |
| 2021-09-30 | 10-Q | 14,409,000 | -69,386,000 | -2.62 | 225,256,000 | -362,705,000 |
| 2021-06-30 | 10-Q | 40,659,000 | -43,668,000 | -1.67 | 280,461,000 | -304,310,000 |
| 2021-03-31 | 10-Q | 7,978,000 | -90,935,000 | -3.50 | 278,606,000 | -269,394,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Koenig Sheldon L. | Director, Officer, President and CEO | Open Market Sale | -25,578 | 2.72 | -69,546.58 | -219,9% | |
| 2026-03-17 | Looker Benjamin | Officer, Chief Legal Officer | Open Market Sale | -5,708 | 2.70 | -15,428.72 | -48,8% | |
| 2026-03-17 | Halladay Benjamin | Officer, Chief Financial Officer | Open Market Sale | -6,424 | 2.71 | -17,376.92 | -54,9% | |
| 2026-01-20 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -1,689 | 2.88 | -4,867.70 | -15,4% | |
| 2025-12-17 | Koenig Sheldon L. | Director, Officer, President and CEO | Open Market Sale | -48,244 | 3.67 | -177,200.21 | -560,2% | |
| 2025-12-17 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -6,517 | 3.67 | -23,897.84 | -75,5% | |
| 2025-12-17 | Halladay Benjamin | Officer, Chief Financial Officer | Open Market Sale | -7,337 | 3.67 | -26,904.78 | -85,1% | |
| 2025-10-17 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -1,248 | 2.62 | -3,275.38 | -10,4% | |
| 2025-09-17 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -6,267 | 2.80 | -17,572.67 | -55,6% | |
| 2025-09-17 | Halladay Benjamin | Officer, Chief Financial Officer | Open Market Sale | -7,046 | 2.81 | -19,785.17 | -62,5% | |
| 2025-09-17 | Koenig Sheldon L. | Director, Officer, President and CEO | Open Market Sale | -28,427 | 2.79 | -79,254.48 | -250,6% | |
| 2025-07-17 | Halladay Benjamin | Officer, Chief Financial Officer | Open Market Sale | -11 | 1.12 | -12.27 | 0,0% | |
| 2025-07-17 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -1,304 | 1.13 | -1,469.61 | -4,6% | |
| 2025-06-17 | Halladay Benjamin | Officer, Chief Financial Officer | Open Market Sale | -7,229 | 1.15 | -8,327.81 | -26,3% | |
| 2025-06-17 | Looker Benjamin | Officer, General Counsel | Open Market Sale | -6,422 | 1.15 | -7,398.14 | -23,4% | |
| 2025-06-17 | Koenig Sheldon L. | Director, Officer, President and CEO | Open Market Sale | -30,474 | 1.11 | -33,795.67 | -106,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.